Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

NCT04042558 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT04042558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
Lead sponsor
Centre Francois Baclesse
Phase
Phase 2
Overall status
Completed
Start date
September 26, 2019
Completion date
April 9, 2025
Enrollment
150 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement positive, egfr gene mutation, nsclc stage iiib, nsclc stage iv, ros1 gene mutation